Our Leaders

Mr. Sibold has served as our President and Chief Executive Officer since September 2023. Mr. Sibold has more than 30 years of experience in the biopharmaceutical industry. From 2017 to September 2023, Mr. Sibold served as Executive Vice President, Specialty Care of Sanofi and President, Sanofi North America, where he led a global organization of approximately 10,000 employees across five specialty therapeutic areas and served as a member of the Sanofi Executive Committee. From 2015 to 2017, Mr. Sibold served as Senior Vice President, Global Franchise Head, Multiple Sclerosis, Oncology & Immunology, Sanofi Genzyme. Mr. Sibold first joined Sanofi Specialty Care in 2011 as Global Franchise Head Multiple Sclerosis. Previously, Mr. Sibold served as Chief Commercial Officer of Avanir Pharmaceuticals, Inc., President and CEO of Lycera Corp., and Senior Vice President, U.S. Commercial for Biogen. Mr. Sibold holds a B.A. in Molecular Biophysics and Biochemistry from Yale University and an M.B.A. from Harvard Business School.

Dr. Taub serves as our Senior Scientific and Medical Advisor. Dr. Taub served as our President, Research & Development from June 2019 and as our Chief Medical Officer from July 2016 until April 2025. Dr. Taub also previously served as our Executive Vice President, Research & Development, from July 2016 through June 2019 and as our Chief Executive Officer from September 2011 to July 2016. Prior to joining us, Dr. Taub served as Senior Vice President, Research and Development of VIA Pharmaceuticals, Inc. from 2008 to 2011 and as Vice President, Research, Metabolic Diseases at F. Hoffmann-La Roche AG from 2004 to 2008. In those positions, Dr. Taub oversaw clinical development and drug discovery programs in cardiovascular and metabolic diseases, including the conduct of a series of Phase 1 and 2 proof of concept clinical trials. From 2000 through 2003, Dr. Taub worked at Bristol-Myers Squibb Company and DuPont, in a variety of positions, including as Executive Director of CNS and metabolic diseases research at each company. Before becoming a pharmaceutical executive, Dr. Taub was a tenured Professor of Genetics and Medicine at the University of Pennsylvania, and remains an adjunct professor. Dr. Taub is the author of more than 120 research articles. Before joining the faculty of the University of Pennsylvania, Dr. Taub served as an Assistant Professor at the Joslin Diabetes Center of Harvard Medical School, Harvard University and an associate investigator with the Howard Hughes Medical Institute. Dr. Taub has served on the board of directors of BriaCell Therapeutics Corp., a publicly traded immuno-oncology biotechnology company, since March 2019. Dr. Taub received her M.D. from Yale University School of Medicine and B.A. from Yale College.

Mr. Baker is a Managing Member of Baker Bros. Advisors LP (“BBA”), a biotechnology-focused investment advisor to fund partnerships whose investors are primarily endowments and foundations. Mr. Baker founded BBA, together with his brother Felix Baker, in 2000. Prior to BBA, Mr. Baker was a portfolio manager at Tisch Financial Management from 1994 to 1999. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation. Mr. Baker has served on the boards of directors of Incyte Corporation since November 2001, Acadia Pharmaceuticals, Inc. since December 2015 and Prelude Therapeutics, Inc. since January 2021, each of which is a publicly traded company. Mr. Baker has also served on the board of directors of Everyone Medicines Inc., a private company, since January 2021. Mr. Baker previously served on the board of directors of Alumis, Inc. until June 2024. Mr. Baker holds an A.B. from Harvard University.

Mr. Bate currently works as an independent consultant. Previously, Mr. Bate was the President and Chief Executive Officer of Archemix Corp., a privately held biopharmaceutical company, from April 2009 through December 2011. From 2006 to April 2009, he served in various positions at NitroMed, Inc., a publicly held pharmaceutical company, most recently as President and Chief Executive Officer. From 2002 to 2005, Mr. Bate served as Head of Commercial Operations and Chief Financial Officer at Millennium Pharmaceuticals, Inc., a biopharmaceutical company. Prior to joining Millennium Pharmaceuticals, Mr. Bate co-founded JSB Partners, LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. From 1990 to 1996, Mr. Bate was employed with Biogen, Inc., a publicly traded biotechnology company, first as its Chief Financial Officer and then as head of the commercial organization responsible for launching Biogen’s multiple sclerosis business. Mr. Bate has served as a member of the board of directors of Astria Therapeutics, Inc., a publicly traded biopharmaceutical company, since January 2014, as co-chair from February 2016 to February 2019, and as chair since February 2019. Mr. Bate previously served on the boards of directors of Genocea Biosciences, Inc., a publicly traded biopharmaceutical company, from 2014 to 2022, and AVEO Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from 2008 until its merger with LG Chem, Ltd. in 2023. Mr. Bate holds a B.A. in Chemistry from Williams College and an M.B.A. from The Wharton School of the University of Pennsylvania.

Dr. Cheong is a Managing Director at Baker Bros. Advisors LP (“BBA”). Prior to joining BBA in 2013, Dr. Cheong completed an M.D. and a Ph.D. in Biomedical Engineering from Johns Hopkins University, where he was awarded the Michael A. Shanoff Award for best thesis research within the School of Medicine. Prior to Johns Hopkins, he earned a B.S. in Chemical Engineering from the University of Maryland, College Park. Dr. Cheong has served on the boards of directors of vTv Therapeutics Inc., a publicly traded biopharmaceutical company, since February 2024, and Istari Oncology, Inc., a private biopharmaceutical company, since December 2018. Dr. Cheong previously served on the board of directors of Talis Biomedical Corporation, a publicly traded company, from June 2020 to June 2022 and from March 2023 to October 2024.

Dr. Craves co-founded and served as Chairman of the Board of Madrigal from its inception in September 2011 through the merger involving Synta Pharmaceuticals Corp., which resulted in Madrigal becoming a public company in July 2016. Dr. Craves is a co-founder of Bay City Capital. In the course of his career, Dr. Craves has founded and managed several biotechnology companies. Dr. Craves previously served on the boards of directors of several privately held and publicly held companies. Dr. Craves currently serves as a member of the board of directors of Synchronicity Pharma, Inc. and IMIDomics, Inc., each a privately held life-science company. During the past five years, Dr. Craves served as a member of the board of directors of Dermira, Inc., KBP Pharmaceuticals, Inc. and Twist Bioscience, Inc., each a publicly held life science company. Dr. Craves earned a B.S. in biology from Georgetown University, an M.S. in biochemical pharmacology from Wayne State University and a Ph.D. in pharmacology and experimental toxicology from the University of California, San Francisco.

Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry. Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation, a publicly traded biopharmaceutical company, from 2012 to 2015. Previously, Mr. Daly worked for Amgen, Inc. and held various leadership positions over a ten-year period, including his most recent role at Amgen as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Earlier in his career, Mr. Daly spent over 16 years with Glaxo Wellcome/GlaxoSmithKline, where he held roles of increasing responsibility, including his most recent role as Senior Vice President, General Manager of the Respiratory and Anti-Infective Business Unit. Mr. Daly has served on the boards of directors of Acadia since January 2016 and argenx SE since May 2018, each a publicly traded company. He previously served on the boards of directors of Chimerix, Inc., a publicly traded company, from June 2014 to June 2020 and Bellicum Pharmaceuticals, Inc., a publicly traded company, from May 2016 to June 2023. Mr. Daly earned a B.S. in Pharmacy and an M.B.A. from the University at Buffalo, The State University of New York.

Dr. Friedman served as our Chairman and Chief Executive Officer from 2016 through September 2023 when he retired from this role. Dr. Friedman served as the Chief Executive Officer of Incyte Corporation from November 2001 to January 2014. From 1994-1998, Dr. Friedman served as President of Research & Development for the DuPont-Merck Pharmaceutical Company and as President of DuPont Pharmaceuticals Research Laboratories, a wholly owned subsidiary of the DuPont Company from 1998 to 2001. From 1991 to 1994, Dr. Friedman served as Senior Vice President at Merck Research Laboratories. Prior to his tenures at Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr. Friedman is a diplomat of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. Dr. Friedman has served on the board of directors of Prelude as non-executive Chairman since July 2016. He also previously served on the boards of directors of Incyte from November 2001 to May 2021 and Alexion Pharmaceuticals, Inc. from September 2017 until its acquisition by AstraZeneca in July 2021. Dr. Friedman received his A.B. in Biology from Princeton University and his M.D. from Harvard Medical School.

Dr. Levy served as Executive Vice President and Chief Drug Development Officer at Incyte Corporation from January 2009 until his retirement in April 2016, and as Senior Vice President of Drug Development at Incyte from August 2003 to January 2009. Prior to joining Incyte, Dr. Levy served as Vice President, Biologic Therapies, at Celgene from 2002 to 2003. From 1997 to 2002, Dr. Levy served in various executive positions with DuPont, first as Vice President, Regulatory Affairs and Pharmacovigilence, and thereafter as Vice President, Medical and Commercial Strategy. Dr. Levy served at Novartis AG, and its predecessor company Sandoz, from 1991 to 1997 in positions of increasing responsibility in clinical research and regulatory affairs. Dr. Levy has more than 30 years of experience in the pharmaceutical and biotechnology industries, has extensive clinical research, regulatory and product development skills and has worked in multiple therapeutic areas. Dr. Levy previously served as a part-time Senior Advisor for Baker Brothers from December 2016 to May 2019. Prior to joining the pharmaceutical industry, Dr. Levy served as an Assistant Professor of Medicine at the UCLA School of Medicine. Dr. Levy has served on the boards of directors of ProTara Therapeutics, Inc. since December 2019, Kodiak Sciences, Inc. since May 2018 and Kiniksa Pharmaceuticals, Ltd. since March 2019, each of which is a publicly traded biopharmaceutical company. Dr. Levy previously served on the board of directors of Constellation Pharmaceuticals Inc., a publicly traded biopharmaceutical company, from April 2020 until it was acquired by MorphoSys AG in July 2021. Dr. Levy is Board Certified in Internal Medicine and Gastroenterology and received his A.B. in Biology from Brown University, his M.D. from the University of Pennsylvania School of Medicine, and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology at UCLA.

Dr. Fouse served as Chief Executive Officer of Agios Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from February 2019 until she retired from this position in August 2022. Prior to Agios, Dr. Fouse served as Executive Chair of Dermavant Sciences, Inc., a biopharmaceutical company, from July 2017 to September 2018. From September 2010 to June 2017, Dr. Fouse served in various capacities at Celgene Corporation, a biopharmaceutical company, serving as Strategic Advisor to the Management Executive Committee from April 2017 to June 2017, President and Chief Operating Officer from March 2016 to March 2017, President, Hematology and Oncology from August 2014 to February 2016, Executive Vice President and Chief Financial Officer from February 2012 to July 2014, and Senior Vice President and Chief Financial Officer from September 2010 to February 2012. Prior to joining Celgene, Dr. Fouse served as Chief Financial Officer of Bunge Limited, a global agribusiness and food company, from July 2007 to September 2010. Prior to joining Bunge Limited, Dr. Fouse served as Senior Vice President, Chief Financial Officer and Corporate Strategy at Alcon Laboratories, Inc. from 2006 to 2007, and as its Senior Vice President and Chief Financial Officer from 2002 to 2006. Prior to her time with Alcon, Dr. Fouse held a variety of senior leadership roles with international companies in Europe, including Swiss International Air Lines AG and Nestle S.A. Dr. Fouse has served as a member of the board of directors of Incyte Corporation since 2017 and has served as the chair of the Agios board of directors since August 2022. Dr. Fouse earned a B.A. and M.A. in Economics and a Ph.D. in Finance from The University of Texas at Arlington.